R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
- Registration Number
- NCT00005843
- Lead Sponsor
- National Cancer Institute (NCI)
- Brief Summary
Phase II trial to study the effectiveness of R115777 in treating patients who have metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Detailed Description
OBJECTIVES:
I. Determine the safety and effectiveness of R115777 in patients with metastatic pancreatic cancer.
II. Determine the response rate, time to progression, and 6 month survival rate of these patients with this treatment regimen.
III. Assess the pharmacokinetics of this treatment regimen in this patient population.
OUTLINE: This is a multicenter study.
Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Arm I tipifarnib Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
University of Texas - MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States